AtriCure, Inc. $ATRC Stock Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al reduced its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 69.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,200 shares of the medical device company’s stock after selling 12,000 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in AtriCure were worth $292,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of ATRC. Verdence Capital Advisors LLC purchased a new stake in shares of AtriCure in the 3rd quarter worth $231,000. Sterling Capital Management LLC increased its stake in shares of AtriCure by 841.1% during the third quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock valued at $93,000 after buying an additional 1,472 shares during the period. Yousif Capital Management LLC purchased a new position in shares of AtriCure during the third quarter valued at $762,000. Net Worth Advisory Group bought a new stake in shares of AtriCure in the third quarter valued at about $305,000. Finally, State of Alaska Department of Revenue raised its holdings in shares of AtriCure by 265.6% in the third quarter. State of Alaska Department of Revenue now owns 10,497 shares of the medical device company’s stock valued at $589,000 after acquiring an additional 7,626 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on ATRC shares. Citizens Jmp upped their price objective on shares of AtriCure from $52.00 to $68.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 21st. Canaccord Genuity Group boosted their price target on shares of AtriCure from $55.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. UBS Group cut shares of AtriCure from a “buy” rating to a “sell” rating in a research report on Wednesday, October 21st. Finally, Freedom Capital downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.80.

Insider Transactions at AtriCure

In other news, insider Salvatore Privitera sold 8,404 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the sale, the insider owned 134,341 shares in the company, valued at approximately $8,732,165. The trade was a 5.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Regina E. Groves sold 5,313 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the transaction, the director owned 34,546 shares in the company, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 39,026 shares of company stock valued at $2,172,263 in the last quarter. 4.00% of the stock is currently owned by corporate insiders.

AtriCure Trading Down 4.5%

ATRC opened at $58.54 on Friday. The company has a current ratio of 4.33, a quick ratio of 3.19 and a debt-to-equity ratio of 0.17. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of 195.14 and a beta of 1.23. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $66.02. The stock has a fifty day moving average price of $56.81 and a 200-day moving average price of $38.73.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.23. The company had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. As a group, equities research analysts anticipate that AtriCure, Inc. will post 0.44 earnings per share for the current fiscal year.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.